When Life Expectancy is Not Short Enough: A Perspective on the National Institute for Health and Care Excellence (NICE) Preliminary Guidance for Dinutuximab

Pediatr Blood Cancer. 2016 Jun;63(6):962-3. doi: 10.1002/pbc.25891. Epub 2016 Jan 6.

Authors

Peter C Adamson¹, Julie R Park², Andrew D Pearson^{3

4}

Affiliations

¹ Children's Oncology Group, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
² Division of Pediatric Hematology and Oncology, Seattle Children's Hospital/University of Washington, Seattle, Washington.
³ Formerly, Division of Clinical Studies, The Institute of Cancer Research, London, UK.
⁴ Formerly, Paediatric Drug Development, Children and Young People's Unit, The Royal Marsden NHS Foundation Trust, Sutton, UK.

PMID: 26740172
DOI: 10.1002/pbc.25891

No abstract available

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents / therapeutic use*
Child
Drug Approval / legislation & jurisprudence
Humans
Life Expectancy*
Neuroblastoma / drug therapy*
United Kingdom

Substances

Antibodies, Monoclonal
Antineoplastic Agents
dinutuximab